Microchip Biotechnologies secures patent rights from Pathwork Diagnostics

Microchip Biotechnologies, Inc. has announced that it has secured key patent rights from Pathwork Diagnostics for sample injection structures in microfluidic separations.

The pending patent relates to improved sample injection structures and methods for defining accurate volumes of material for microfluidic separations. Financial terms of the transaction were not released.

"The addition of this intellectual property to our patent portfolio builds upon our strong patent position in microfluidic devices for life science, applied sciences, and diagnostic products," said Dr. Stevan Jovanovich, President and CEO of MBI. "Microfluidic devices will play a critical role in next-generation instrumentation to deliver fully automated, cost effective solutions for laboratory and field based applications."

The acquired pending patent was held previously by Predicant Biosciences, which in a June 2006 merger became Pathwork Diagnostics, a genomics-based diagnostics company focused on oncology.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
A promising visual sign for concussion diagnosis in athletes